Home / Recalls / Wells Pharma of Houston LLC / D-0508-2026

D-0508-2026 Class II Ongoing

Recalled by Wells Pharma of Houston LLC — Houston, TX

Recall Details

Product Type
Drugs
Report Date
May 6, 2026
Initiation Date
April 1, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
50 syringes

Product Description

fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 50 mcg/5mL)(10 mcg per mL), wells pharma, NDC 73702-202-15.

Reason for Recall

cGMP deviations.

Distribution Pattern

U.S. Nationwide.

Code Information

Lot 020226202150202, Exp Date 05/05/2026.

Other recalls by Wells Pharma of Houston LLC

  • D-0507-2026 Class II — Ketamine Hydrochloride Injectable Solution, 50mg/ml, (50 mg per mL) Volume: 1 mL (April 1, 2026)
  • D-0504-2026 Class II — fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride, Narcotic, (2500 mc (April 1, 2026)
  • D-0505-2026 Class II — fentaNYL Citrate Injectable Solution, Narcotic, CII, 1250 mcg/25mL (50 mcg per m (April 1, 2026)
  • D-0503-2026 Class II — fentaNYL Citrate Injectable Solution, NARCOTIC, Cii, 1000 mcg/100 mL (10 mcg per (April 1, 2026)
  • D-0506-2026 Class II — fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride, 1000 mcg/50mL (20 (April 1, 2026)
  • D-0502-2026 Class II — Phenylephrine Hydrochloride Injectable Solution, 40mg, 250*mL Bag, wells pharma (April 1, 2026)
  • D-0141-2024 Class II — ceFAZolin sodium in Sterile Water for injection, Injectable Solution, 1g/10mL (0 (November 22, 2023)